Precision BioSciences, Inc. entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock…
PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events As previously reported, on November 5, 2026, Precision BioSciences, Inc. (the “Company”) entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share (the “Co
How this was made
The 30-second read
Why it matters
The infusion of cash improves runway for its HBV and DMD programs, likely stabilizing the stock and offering a short‑term catalyst.
Market read
Primary disclosure of a sizable financing event for a micro‑cap biotech, offering a modest trading catalyst.
What to watch
Potential covenant restrictions from the underwriting agreement or future financing needs beyond 2029.
Background
Precision BioSciences disclosed a primary capital‑raising event via an 8‑K filing, detailing share price, quantity, and intended use of proceeds.
Ticker impact
Precision BioSciences filed an 8‑K announcing an underwriting agreement to issue 10,235,077 shares at $7.75 each, raising roughly $79 million for cash runway through Q4 2029.
modest upside as the market prices in the strengthened balance sheet and extended runway
New financing of ~ $80 M is material for a micro‑cap biotech; investors typically view cash infusions positively unless accompanied by heavy dilution.
Market effects
Adds cash to the gene‑therapy sector, potentially boosting sentiment for similar biotech pipelines.
Limited to U.S. biotech investors; no broader regional effect.
Minor global impact; primarily relevant to niche biotech investors.
Counterpoint
The dilution from issuing 10 M new shares could pressure the stock if the market questions the valuation of the raise.
Key entities
- companyPrecision BioSciences, Inc.
Biotech firm developing gene‑editing therapies.
